Abstract
Prostate cancer is the second most frequent men’s cancer diagnosis and the fifth leading cause of death worldwide. A large percentage of prostate cancers are initially very sensitive to hormone therapies, but over time the sensitivity to antiandrogens may be lost and cancers can develop resistance through various signalling mechanisms. Expression of the androgen receptor splice variant 7 (AR-V7) in some cases is considered as one of the factors supporting antiandrogen resistance. The study aims to develop novel AR-V7 inhibitors for prostate cancer therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
